Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: 2 | Rare Historical Photos

Adding a Muscle Targeting Antibody to Semaglutide Cut Lean Mass Loss from 7.4% to 2.9% in a Phase 2 Trial

A 507-person trial found bimagrumab plus semaglutide protected lean mass while increasing fat loss. The drug remains investigational.

Medical Daily

Bank of America CEO Says The Company Spends $250 Million A Year on GLP-1 Drugs for Their Employees. He Calls It a Good Investment

Bank of America CEO Brian Moynihan said the company has dramatically increased its investment in medications such as Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Zepbound.

International Business Times

LLY Stock Alert: What to Know as Eli Lilly Teams Up With CVS on Weight-Loss Drugs

Eli Lilly shares rally on a fresh DTC partnership with CVS Health. A strong Q2 release and impressive future guidance is driving LLY stock higher as well.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

Eli Lilly and Co. (NYSE:LLY) stock traded higher Wednesday after the drugmaker reported second-quarter results that topped Wall Street expectations and raised its full-year revenue outlook, driven by continued demand for its diabetes and obesity treatments.

Benzinga

Eli Lilly Raises Sales Forecast As Weight Loss Drug Demand Soars. Its Stock is Climbing

Eli Lilly posted stronger-than-expected second-quarter earnings and revenue, boosted by surging demand for Zepbound and Mounjaro, while its newly launched obesity pill Foundayo made its first contribution to quarterly sales.

International Business Times

Mounjaro sales double this year as obesity drug boom prevails, says maker

The manufacturer said its obesity medications Mounjaro and Zepbound were driving an acceleration of its overall sales.

Evening Standard

Sales in weight-loss drug Mounjaro double amid surging market appetite

Eli Lilly’s chief executive David Ricks told investors that it was ‘building for the future’

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Could Swing $65.9 Billion After Earnings

Earnings are set to hit the tape in a tight window on Wednesday and the options market is already sketching out how much volatility traders are willing to pay for into the prints, according to Benzinga Pro.

Benzinga

Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb

U.S.-listed shares of Novo Nordisk fell more than 6% after the company raised its full-year 2026 outlook but signaled that sales and profit could still decline compared with the previous year.

International Business Times

A Next-Generation Obesity Drug Has Been Released By Eli Lilly in Early Access to Select Patients

Eli Lilly will offer early access to the investigational obesity drug retatrutide after positive Phase 3 trials showed significant weight-loss results.

Medical Daily

Michigan Supreme Court Clears the Way for a State Investigation into Eli Lilly Insulin Pricing

Michigan's high court ruled 4-3 that the state may investigate Eli Lilly's insulin pricing. The decision authorizes a probe, not a finding of wrongdoing.

Medical Daily

What Is Retatrutide? The Next-Gen GLP-1 Poised to Become the Most In-Demand Peptide

A deep dive into Retatrutide shows promise—and a lot of danger.

Marie Claire

Earnings, PMI and Other Key Things to Watch this Week

Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.

Barchart

Daily Oral Weight Loss Pill Outperformed Oral Semaglutide On Weight And Blood Sugar In Type 2 Diabetes

In a 1,698-person trial, orforglipron beat oral semaglutide on A1C and weight in type 2 diabetes. Here is what was measured and what was not.

Medical Daily

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads

Novo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers about treatment comparisons. Lilly denies wrongdoing and stands by its advertising claims. Both companies compete in the growing obesity and diabetes drug market. Novo Nordisk argues Lilly uses outdated…

International Business Times

Eli Lilly Cleared Two More Trials For Its Next-Generation Obesity Drug. It Will Seek FDA Approval Next Year

After 80 weeks of treatment, obese, non-diabetic participants receiving retatrutide lost an average of 22.6% of their body weight while also showing improvements in several cardiometabolic risk factors.

Bored Panda

The New Drug Melting Body Fat From 38% To 22% — And The Side Effect Patients Are Ignoring

A new weight loss drug is drawing serious attention from the medical community, and the comparisons to Ozempic are coming quickly. But researchers are pointing to one difference between the two that is proving difficult to overlook, and it may change how the conversation around weight loss medication develops from…

Medical Daily

The First Oral GLP-1 Weight Loss Pill With No Food or Injection Requirements Is Now Available

Eli Lilly's Foundayo (orforglipron) is the first oral GLP-1 obesity pill with no food or water restrictions. FDA approved it April 1, 2026. Here is what patients should know.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Insider Moves Are Sending Mixed Signals Across the Tech Sector

Broadcom sees insider selling after volatile 2026 trading, while Netskope draws heavy insider buying post-earnings drop and Eli Lilly CEO David Ricks purchases Adobe shares.

The Independent UK

Two weight-loss drugmakers in legal battle over which is most effective in helping users shed pounds

Novo Nordisk claims Eli Lilly compared peak doses of Zepbound against outdated, lower doses of Wegovy to advertise a 50-pound weight loss versus 33 pounds

International Business Times

Novo Nordisk Says Eli Lilly Used Misleading Weight Loss Drug Advertising. It's Suing

The lawsuit, filed Tuesday, alleges that Eli Lilly violated federal and state false advertising laws by promoting "knowingly outdated clinical trial" results that compare both companies' drugs.

The Economic Times

Novo Nordisk sues Eli Lilly, accusing it of false advertising of weight-loss drug

Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo claims Lilly compared lower doses of its drugs with higher doses of Lilly's. Lilly's advertisements allegedly omit newer, higher-dose versions of Novo's medicines. Novo seeks to withdraw…

Kiplinger

Nasdaq Sinks as Chip Stocks Drop Again: Stock Market Today

While Taiwan Semi's post-earnings drop pressured chipmakers, healthcare names outperformed thanks to Merck's FDA win and Eli Lilly's big buy.

International Business Times

Eli Lilly Changed Depression Care With Prozac. Now It's Betting on Psychedelics with AtaiBeckley Acquisition

Eli Lilly is making its biggest move yet into the rapidly evolving field of psychedelic medicine, acquiring clinical-stage biotechnology company AtaiBeckley in a deal valued at up to $3.8 billion.

Barchart

Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock

Eli Lilly stock rallies on a $2.8 billion acquisition of AtaiBeckley. Here’s why the deal is bullish for LLY shares.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.